Efficacy of Corticosteroids in Patients With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis

IF 2.5 3区 医学 Q3 IMMUNOLOGY
Silvia D'Ippolito, Filippo Gavi, Chiara Granieri, Chiara De Waure, Sara Giuliano, Francesco Cosentino, Chiara Tersigni, Giovanni Scambia, Nicoletta Di Simone
{"title":"Efficacy of Corticosteroids in Patients With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis","authors":"Silvia D'Ippolito,&nbsp;Filippo Gavi,&nbsp;Chiara Granieri,&nbsp;Chiara De Waure,&nbsp;Sara Giuliano,&nbsp;Francesco Cosentino,&nbsp;Chiara Tersigni,&nbsp;Giovanni Scambia,&nbsp;Nicoletta Di Simone","doi":"10.1111/aji.70037","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Recurrent pregnancy loss (RPL) represents a complication of pregnancy occurring in 1%–3% of all couples trying to conceive. About 50%–60% of RPL cases remain idiopathic, therefore therapeutic strategies seem empirical and based on unproven evidence. We investigated the efficacy of corticosteroids in women with RPL. We conducted a systematic review and meta-analysis, up to August 2024, in the PubMed, Scopus, and Web of Science databases, including studies on idiopathic RPL women and comparing corticosteroids versus control treatment. Primary outcome was the ongoing pregnancy rate beyond 12 weeks of gestation; secondary outcomes were live birth rate (LBR), stillbirth, birth weight, incidence of preeclampsia and/or gestational diabetes, gestational age at delivery, and fetal abnormalities. Four studies comprising 417 RPL women randomly assigned to steroid or control treatment were included. We found that oral corticosteroids significantly increase the ongoing pregnancy rate beyond 12 weeks of gestation compared to the control group (log OR [odds ratio] = 1.49 [0.32, 2.67], <i>p</i> = 0.01), with high heterogeneity (<i>I</i><sup>2</sup> = 75%), and improve LBR (log OR = 0.9 [0.11, 1.69], <i>p</i> = 0.03), with low heterogeneity (<i>I</i><sup>2</sup> = 0.05%). However, the limited number of studies significantly limits the strength of the findings. Also, the benefit/risk assessment of the use of corticosteroids in early pregnancy for RPL is still unclear.</p>\n </div>","PeriodicalId":7665,"journal":{"name":"American Journal of Reproductive Immunology","volume":"93 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Reproductive Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aji.70037","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Recurrent pregnancy loss (RPL) represents a complication of pregnancy occurring in 1%–3% of all couples trying to conceive. About 50%–60% of RPL cases remain idiopathic, therefore therapeutic strategies seem empirical and based on unproven evidence. We investigated the efficacy of corticosteroids in women with RPL. We conducted a systematic review and meta-analysis, up to August 2024, in the PubMed, Scopus, and Web of Science databases, including studies on idiopathic RPL women and comparing corticosteroids versus control treatment. Primary outcome was the ongoing pregnancy rate beyond 12 weeks of gestation; secondary outcomes were live birth rate (LBR), stillbirth, birth weight, incidence of preeclampsia and/or gestational diabetes, gestational age at delivery, and fetal abnormalities. Four studies comprising 417 RPL women randomly assigned to steroid or control treatment were included. We found that oral corticosteroids significantly increase the ongoing pregnancy rate beyond 12 weeks of gestation compared to the control group (log OR [odds ratio] = 1.49 [0.32, 2.67], p = 0.01), with high heterogeneity (I2 = 75%), and improve LBR (log OR = 0.9 [0.11, 1.69], p = 0.03), with low heterogeneity (I2 = 0.05%). However, the limited number of studies significantly limits the strength of the findings. Also, the benefit/risk assessment of the use of corticosteroids in early pregnancy for RPL is still unclear.

皮质类固醇治疗复发性流产患者的疗效:一项系统综述和荟萃分析。
复发性妊娠丢失(RPL)是一种妊娠并发症,发生在所有试图怀孕的夫妇中1%-3%。大约50%-60%的RPL病例仍然是特发性的,因此治疗策略似乎是经验性的,基于未经证实的证据。我们研究了皮质类固醇对女性RPL的疗效。截至2024年8月,我们在PubMed、Scopus和Web of Science数据库中进行了系统回顾和荟萃分析,包括特发性RPL女性的研究,并比较了皮质类固醇与对照治疗。主要结局是妊娠超过12周的持续妊娠率;次要结局是活产率(LBR)、死产、出生体重、先兆子痫和/或妊娠糖尿病的发生率、分娩胎龄和胎儿异常。包括417名RPL妇女的四项研究,随机分配到类固醇或对照治疗。我们发现,与对照组相比,口服皮质类固醇显著增加妊娠12周以上的持续妊娠率(对数OR[比值比]= 1.49 [0.32,2.67],p = 0.01),异质性高(I2 = 75%),改善LBR(对数OR = 0.9 [0.11, 1.69], p = 0.03),异质性低(I2 = 0.05%)。然而,有限的研究数量极大地限制了研究结果的强度。此外,在妊娠早期使用皮质类固醇治疗RPL的获益/风险评估仍不清楚。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
5.60%
发文量
314
审稿时长
2 months
期刊介绍: The American Journal of Reproductive Immunology is an international journal devoted to the presentation of current information in all areas relating to Reproductive Immunology. The journal is directed toward both the basic scientist and the clinician, covering the whole process of reproduction as affected by immunological processes. The journal covers a variety of subspecialty topics, including fertility immunology, pregnancy immunology, immunogenetics, mucosal immunology, immunocontraception, endometriosis, abortion, tumor immunology of the reproductive tract, autoantibodies, infectious disease of the reproductive tract, and technical news.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信